Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S-268019-b COVID-19 vaccine prevention trial
NCT05212948Phase 3Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Dec 2021
- Primary completion
- Dec 2022
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of S-268019-b in coronavirus disease 2019 (COVID-19), sponsored by Shionogi & Co., Ltd.. Started Dec 2021; status: completed.
02
Drugs
S-268019-b
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05212948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05212948.